Jeena Sikho Lifecare Past Earnings Performance
Past criteria checks 5/6
Jeena Sikho Lifecare has been growing earnings at an average annual rate of 40.8%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 38.5% per year. Jeena Sikho Lifecare's return on equity is 36.8%, and it has net margins of 22.1%.
Key information
40.8%
Earnings growth rate
38.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 38.5% |
| Return on equity | 36.8% |
| Net Margin | 22.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Investors Shouldn't Be Too Comfortable With Jeena Sikho Lifecare's (NSE:JSLL) Earnings
Nov 23
Jeena Sikho Lifecare's (NSE:JSLL) Earnings Are Weaker Than They Seem
May 24Recent updates
Investors Shouldn't Be Too Comfortable With Jeena Sikho Lifecare's (NSE:JSLL) Earnings
Nov 23Why Investors Shouldn't Be Surprised By Jeena Sikho Lifecare Limited's (NSE:JSLL) 31% Share Price Surge
Aug 20Jeena Sikho Lifecare (NSE:JSLL) Will Pay A Larger Dividend Than Last Year At ₹4.18
Aug 01Jeena Sikho Lifecare's (NSE:JSLL) Earnings Are Weaker Than They Seem
May 24Should You Be Adding Jeena Sikho Lifecare (NSE:JSLL) To Your Watchlist Today?
Apr 03With Jeena Sikho Lifecare Limited (NSE:JSLL) It Looks Like You'll Get What You Pay For
Feb 08Here's Why We Think Jeena Sikho Lifecare (NSE:JSLL) Is Well Worth Watching
Nov 01With EPS Growth And More, Jeena Sikho Lifecare (NSE:JSLL) Makes An Interesting Case
Jul 15Jeena Sikho Lifecare Limited's (NSE:JSLL) Shares Climb 41% But Its Business Is Yet to Catch Up
Nov 18Jeena Sikho Lifecare's (NSE:JSLL) Solid Profits Have Weak Fundamentals
Aug 02Calculating The Intrinsic Value Of Jeena Sikho Lifecare Limited (NSE:JSLL)
Jul 21Revenue & Expenses Breakdown
How Jeena Sikho Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,812 | 843 | 1,409 | 0 |
| 30 Jun 24 | 3,528 | 767 | 1,335 | 0 |
| 31 Mar 24 | 3,244 | 692 | 1,262 | 0 |
| 31 Dec 23 | 2,989 | 618 | 1,077 | 0 |
| 30 Sep 23 | 2,752 | 545 | 903 | 0 |
| 30 Jun 23 | 2,400 | 442 | 850 | 0 |
| 31 Mar 23 | 2,039 | 337 | 791 | 0 |
| 31 Mar 22 | 1,466 | 112 | 706 | 0 |
| 31 Mar 21 | 1,358 | 102 | 650 | 0 |
| 31 Mar 20 | 944 | 57 | 216 | 0 |
| 31 Mar 19 | 1,058 | 60 | 144 | 0 |
Quality Earnings: JSLL has a high level of non-cash earnings.
Growing Profit Margin: JSLL's current net profit margins (22.1%) are higher than last year (19.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSLL's earnings have grown significantly by 40.8% per year over the past 5 years.
Accelerating Growth: JSLL's earnings growth over the past year (54.5%) exceeds its 5-year average (40.8% per year).
Earnings vs Industry: JSLL earnings growth over the past year (54.5%) exceeded the Pharmaceuticals industry 20%.
Return on Equity
High ROE: JSLL's Return on Equity (36.8%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 10:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jeena Sikho Lifecare Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|